Straits Times Index
3,301.48 +8.79 (+0.27%) Nikkei
38,249.94 -24.11 (-0.06%) Hang Seng
18,155.28 +392.25 (+2.21%) FTSE 100
8,121.24 -22.89 (-0.28%) Bitcoin USD
57,415.11 -2,806.21 (-4.66%) CMC Crypto 200
1,261.27 -77.79 (-5.81%)
Cardiff Oncology, Inc. (CRDF)
After hours:
| Previous close | 4.3600 |
| Open | 4.3800 |
| Bid | 4.1800 x 100 |
| Ask | 4.2500 x 400 |
| Day's range | 4.1500 - 4.4500 |
| 52-week range | 0.9400 - 6.4200 |
| Volume | |
| Avg. volume | 1,932,227 |
| Market cap | 189.125M |
| Beta (5Y monthly) | 1.97 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.9300 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 10.50 |
GlobeNewswireCardiff Oncology to Report First Quarter 2024 Results and Provide Business Update
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that it plans to release financial results for the first quarter ended March 31, 2024 on Thursday, May 2 after the close of trading. Conference Call and Webcast Cardiff Oncology will host
- GlobeNewswire
Cardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical Study
RAS-mutated mCRC – In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor’s ability to adapt to hypoxia resulting in a significant decrease in both tumor vascularization and growth – – Enhanced clinical efficacy signal in bev naïve patients in Phase 1b/2 trial is consistent with results of randomized ONSEMBLE trial providing two independent data sets in second-line mCRC validating our strategy to evaluate onvansertib in combination with chemo/bev in RAS-mutate
- GlobeNewswire
Cardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024
SAN DIEGO, March 06, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced publications of five abstracts that will be presented in a poster session at the American Association for Cancer Research (AACR) Annual Meeting, taking place from April 5-10, 2024, in San Diego, California. “The posters we will be presenting at this year’s AACR meeting represent
